Azenta, Inc. (NASDAQ:AZTA) Holdings Reduced by Conestoga Capital Advisors LLC

Conestoga Capital Advisors LLC reduced its stake in shares of Azenta, Inc. (NASDAQ:AZTA - Free Report) by 25.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 956,051 shares of the company's stock after selling 327,188 shares during the period. Conestoga Capital Advisors LLC owned 1.77% of Azenta worth $46,311,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Norden Group LLC purchased a new position in shares of Azenta in the 1st quarter worth about $1,720,000. BNP Paribas Financial Markets raised its holdings in Azenta by 43.5% in the first quarter. BNP Paribas Financial Markets now owns 13,672 shares of the company's stock valued at $824,000 after buying an additional 4,144 shares during the period. Janney Montgomery Scott LLC lifted its position in Azenta by 9.3% during the first quarter. Janney Montgomery Scott LLC now owns 5,167 shares of the company's stock valued at $311,000 after buying an additional 438 shares in the last quarter. Capstone Investment Advisors LLC purchased a new stake in Azenta during the first quarter worth approximately $317,000. Finally, Nordea Investment Management AB increased its position in shares of Azenta by 10.5% in the first quarter. Nordea Investment Management AB now owns 71,855 shares of the company's stock worth $4,386,000 after acquiring an additional 6,833 shares in the last quarter. Hedge funds and other institutional investors own 99.08% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on AZTA. Evercore ISI reduced their target price on shares of Azenta from $53.00 to $50.00 and set an "in-line" rating on the stock in a report on Tuesday, October 1st. Needham & Company LLC reissued a "buy" rating and issued a $69.00 price objective on shares of Azenta in a research report on Wednesday, August 7th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Azenta presently has an average rating of "Hold" and a consensus target price of $66.40.

Insider Buying and Selling

In other Azenta news, CFO Herman Cueto sold 1,595 shares of the stock in a transaction that occurred on Thursday, October 17th. The stock was sold at an average price of $43.68, for a total transaction of $69,669.60. Following the transaction, the chief financial officer now owns 24,604 shares of the company's stock, valued at $1,074,702.72. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 1.77% of the company's stock.

Azenta Trading Up 0.3 %

AZTA stock traded up $0.13 during trading on Friday, reaching $41.22. The stock had a trading volume of 497,990 shares, compared to its average volume of 492,533. The firm has a fifty day moving average price of $46.31 and a 200 day moving average price of $50.93. The company has a market capitalization of $2.02 billion, a P/E ratio of -14.67 and a beta of 1.47. Azenta, Inc. has a 1-year low of $40.24 and a 1-year high of $69.16.

Azenta (NASDAQ:AZTA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.16 earnings per share for the quarter, beating analysts' consensus estimates of $0.07 by $0.09. Azenta had a positive return on equity of 0.89% and a negative net margin of 23.66%. The firm had revenue of $173.00 million during the quarter, compared to analyst estimates of $166.14 million. During the same quarter last year, the firm earned $0.13 EPS. Azenta's quarterly revenue was up 4.2% on a year-over-year basis. Sell-side analysts predict that Azenta, Inc. will post 0.33 EPS for the current year.

Azenta Company Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.